Biblio
Export 956 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is F [Clear All Filters]
“Genotyping of the Alzheimer's Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort.”, J Alzheimers Dis, vol. 64, no. 2, pp. 355-362, 2018.
, “Geographical Distribution and Diversity of Gut Microbial NADH:Ubiquinone Oxidoreductase Sequence Associated with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1531-1540, 2018.
, “Ginkgo biloba Extract EGb 761 and Its Specific Components Elicit Protective Protein Clearance Through the Autophagy-Lysosomal Pathway in Tau-Transgenic Mice and Cultured Neurons.”, J Alzheimers Dis, vol. 65, no. 1, pp. 243-263, 2018.
, “Gut Microbiome is Altered in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1337-1346, 2018.
, “The GWAS Risk Genes for Depression May Be Actively Involved in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1149-1161, 2018.
, “The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort.”, J Alzheimers Dis, vol. 61, no. 2, pp. 753-760, 2018.
, “Hippocampal Stratum Radiatum, Lacunosum, and Moleculare Sparing in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 1, pp. 415-424, 2018.
, “Homocysteine and Dementia: An International Consensus Statement.”, J Alzheimers Dis, vol. 62, no. 2, pp. 561-570, 2018.
, “Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1147-1157, 2018.
, “Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies and ω-3 Not Working in Clinical Trials?”, J Alzheimers Dis, vol. 62, no. 3, pp. 1013-1022, 2018.
, “Increased Prevalence of Obesity/Type 2 Diabetes and Lower Levels of Lithium in Rural Texas Counties May Explain Greater Alzheimer's Disease Risk.”, J Alzheimers Dis, vol. 64, no. 1, pp. 303-308, 2018.
, “Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1201-1219, 2018.
, “The Independent Associations of Physical Activity and Sleep with Cognitive Function in Older Adults.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1469-1484, 2018.
, “Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1663-1681, 2018.
, “Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1663-1681, 2018.
, “The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Neurological Function after Traumatic Brain Injury.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1055-1064, 2018.
, “Inhibition of Histone Acetylation by ANP32A Induces Memory Deficits.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1537-1546, 2018.
, “Interactions between Atrial Fibrillation, Cardiovascular Risk Factors, and ApoE Genotype in Promoting Cognitive Decline in Patients with Alzheimer's Disease: A Prospective Cohort Study.”, J Alzheimers Dis, vol. 62, no. 2, pp. 713-725, 2018.
, “Internal Consistency Over Time of Subjective Cognitive Decline: Drawing Preclinical Alzheimer's Disease Trajectories.”, J Alzheimers Dis, vol. 66, no. 1, pp. 173-183, 2018.
, “Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 2, pp. 551-561, 2018.
, “Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 2, pp. 551-561, 2018.
, “Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 63, no. 1, pp. 149-155, 2018.
, “Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition.”, J Alzheimers Dis, vol. 61, no. 2, pp. 773-783, 2018.
, “Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 689-707, 2018.
, “Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 3, pp. 751-760, 2018.
,